NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

NOVO.B.DK

245.35

-3.39%↓

HLUNB.DK

39.34

+0.87%↑

AMBUB.DK

79.25

+0.57%↑

Search

Coloplast A-S (Class B)

Open

492.5 2.65

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

481.7

Max

494.8

Schlüsselkennzahlen

By Trading Economics

Einkommen

522M

1.4B

Verkäufe

83M

7B

KGV

Branchendurchschnitt

27.421

110.024

EPS

6.32

Dividendenrendite

4.84

Gewinnspanne

19.835

Angestellte

16,983

EBITDA

309M

2.3B

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+11.86% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

4.84%

2.26%

Nächstes Ergebnis

12. Mai 2026

Nächste Dividendenausschüttung

20. Mai 2026

Nächstes Ex-Dividendendatum

18. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-9.1B

110B

Vorheriger Eröffnungskurs

489.85

Vorheriger Schlusskurs

492.5

Coloplast A-S (Class B) Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

23. Feb. 2026, 22:53 UTC

Akquisitionen, Fusionen, Übernahmen

Keurig Dr Pepper Raises Additional $1.5 Billion in Deal to Split Company

23. Feb. 2026, 22:36 UTC

Ergebnisse

Kratos Defense & Security Solutions 4Q Profit Rises; Sees Federal Shutdown Denting 1Q -- Update

23. Feb. 2026, 22:32 UTC

Ergebnisse

Woodside Energy Fiscal Year Net Profit Falls 24%

23. Feb. 2026, 23:58 UTC

Market Talk
Ergebnisse

Plenty of Questions for Woodside Despite Well-Guided Result -- Market Talk

23. Feb. 2026, 23:58 UTC

Market Talk
Ergebnisse

Global Energy Roundup: Market Talk

23. Feb. 2026, 23:47 UTC

Market Talk

Scentre's Share Price Slips as Earnings Guidance Underwhelms -- Market Talk

23. Feb. 2026, 23:43 UTC

Market Talk

Gold Edges Higher Amid Ongoing Tariff Risks -- Market Talk

23. Feb. 2026, 23:41 UTC

Akquisitionen, Fusionen, Übernahmen

Crescent Capital Partners Owns 53% of ClearView Wealth

23. Feb. 2026, 23:40 UTC

Akquisitionen, Fusionen, Übernahmen

ClearView Wealth Says Crescent Capital Partners Intends to Support Deal

23. Feb. 2026, 23:40 UTC

Akquisitionen, Fusionen, Übernahmen

ClearView Wealth Says Directors Unanimously Recommend Shareholders Vote in Favor of Deal

23. Feb. 2026, 23:40 UTC

Market Talk

Nikkei May Rise as Investors Assess Tariff Developments -- Market Talk

23. Feb. 2026, 23:40 UTC

Akquisitionen, Fusionen, Übernahmen

ClearView Wealth Says Zurich Insurance Offering A$0.65/Share in Cash

23. Feb. 2026, 23:39 UTC

Akquisitionen, Fusionen, Übernahmen

ClearView Wealth Agrees to Takeover by Zurich Insurance Group Unit

23. Feb. 2026, 23:31 UTC

Ergebnisse

United Overseas Bank 2025 Total Dividend S$1.56/Shr >U11.SG

23. Feb. 2026, 23:31 UTC

Ergebnisse

United Overseas Bank Proposes Final Dividend of S$0.71/Shr Vs. S$0.92/Shr >U11.SG

23. Feb. 2026, 23:28 UTC

Ergebnisse

United Overseas Bank 4Q Net Interest Income S$2.35B Vs. S$2.45B >U11.SG

23. Feb. 2026, 23:28 UTC

Ergebnisse

United Overseas Bank 4Q Oper Pft S$1.76B Vs. Pft S$1.88B >U11.SG

23. Feb. 2026, 23:28 UTC

Ergebnisse

United Overseas Bank 4Q Total Income S$3.29B Vs. S$3.46B >U11.SG

23. Feb. 2026, 23:27 UTC

Ergebnisse

United Overseas Bank 4Q Net S$1.41B Vs. Net S$1.52B >U11.SG

23. Feb. 2026, 23:24 UTC

Market Talk

Major Miners On Whole Delivered Positive Earnings Season -- Market Talk

23. Feb. 2026, 22:38 UTC

Akquisitionen, Fusionen, Übernahmen

Keurig Dr Pepper Raises Additional $1.5B in Deal to Split Company

23. Feb. 2026, 22:31 UTC

Ergebnisse

Hims & Hers Stock Falls. Why Earnings Are Underwhelming Investors. -- Barrons.com

23. Feb. 2026, 22:24 UTC

Ergebnisse

Viva Energy Energy & Infrastructure Ebitda A$93 Million

23. Feb. 2026, 22:22 UTC

Ergebnisse

Viva Energy FY Commercial & Industrial Ebitda A$460.5 Million

23. Feb. 2026, 22:22 UTC

Ergebnisse

Viva Energy FY Convenience & Mobility Ebitda A$197.4 Million

23. Feb. 2026, 22:22 UTC

Ergebnisse

Viva Energy FY Underlying Ebitda A$700.9 Million

23. Feb. 2026, 22:22 UTC

Ergebnisse

Viva Energy Final Dividend 3.94 Australian Cents/Security

23. Feb. 2026, 22:21 UTC

Ergebnisse

Viva Energy FY Revenue A$28.53 Billion, Down 1.1%

23. Feb. 2026, 22:21 UTC

Ergebnisse

Viva Energy FY Replacement-Cost Net Profit A$183.6 Million, Down 28%

23. Feb. 2026, 22:20 UTC

Ergebnisse

Viva Energy FY Historical-Cost Net Loss A$421.1 Million

Peer-Vergleich

Kursveränderung

Coloplast A-S (Class B) Prognose

Kursziel

By TipRanks

11.86% Vorteil

12-Monats-Prognose

Durchschnitt 901.38 DKK  11.86%

Hoch 1,056 DKK

Tief 720 DKK

Basierend auf 8 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Coloplast A-S (Class B) – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

8 ratings

2

Buy

4

Halten

2

Sell

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat